GGrantIndex
← Leaderboards

Barry Ryan Lutz

University Of Washington

$10,006,881
Attributed
$10,534,601
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY201625
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,534,601 · 9

By mechanism

R01$5,718,119 · 2
R21$1,639,901 · 4
R33$1,502,218 · 1
R61$1,374,597 · 1
R44$299,766 · 1

Top collaborators

Most similar at University Of Washington

Same institution · by research overlap

Others in their field

Top investigators on “Sampling

Research focus

SamplingPoint Of CareCostDetectionDesignPreparationReportingReagentBaseVirusResourcesSiteDevicesFailureViral Load ResultDrug ResistanceTreatment FailurePerformanceInnovationDiagnosisAdherenceOperationLateralMonitor

Grant awards (23)

V-OLA point-of-care HIV viral load monitoring and drug resistance testing$694,837
R01 · FY2025 · AI · contact PI
Quantifying integrase resistance among Nigerian children failing dolutegravir to inform rapid diagnostic development in partnership with Nigerian scientists$418,170
R01 · FY2025 · AI
V-OLA point-of-care HIV viral load monitoring and drug resistance testing$712,118
R01 · FY2024 · AI · contact PI
Quantifying integrase resistance among Nigerian children failing dolutegravir to inform rapid diagnostic development in partnership with Nigerian scientists$337,504
R01 · FY2024 · AI
V-OLA: point-of-care HIV viral load monitoring and drug resistance testing$685,681
R01 · FY2023 · AI · contact PI
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoring$756,232
R33 · FY2022 · AI · contact PI
V-OLA: point-of-care HIV viral load monitoring and drug resistance testing$687,984
R01 · FY2022 · AI · contact PI
Engineering a denaturant-resistant polymerase for direct nucleic acid diagnostics$184,554
R21 · FY2022 · AI · contact PI
Transrenal DNA for point-of-care diagnosis of TB$182,912
R21 · FY2022 · AI · contact PI
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoring$745,986
R33 · FY2021 · AI · contact PI
V-OLA: point-of-care HIV viral load monitoring and drug resistance testing$706,135
R01 · FY2021 · AI · contact PI
Transrenal DNA for point-of-care diagnosis of TB$211,416
R21 · FY2021 · AI · contact PI
Engineering a denaturant-resistant polymerase for direct nucleic acid diagnostics$211,050
R21 · FY2021 · AI · contact PI
V-OLA: point-of-care HIV viral load monitoring and drug resistance testing$722,093
R01 · FY2020 · AI · contact PI
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoring$446,366
R61 · FY2020 · AI · contact PI
V-OLA: point-of-care HIV viral load monitoring and drug resistance testing$753,597
R01 · FY2019 · AI · contact PI
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoring$461,731
R61 · FY2019 · AI · contact PI
Rapid, Multiplexed Point-Of-Care Molecular Detection of Respiratory Pathogens without Sample Prep$299,766
R44 · FY2019 · AI
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoring$466,500
R61 · FY2018 · AI · contact PI
Enabling infant HIV diagnosis in remote settings: a highly-sensitive test with an ASSURED design$155,375
R21 · FY2018 · NR · contact PI
Enabling infant HIV diagnosis in remote settings: a highly-sensitive test with an ASSURED design$269,719
R21 · FY2017 · NR · contact PI
Point-of-care diagnosis of pulmonary TB from urine samples$154,500
R21 · FY2017 · AI · contact PI
Point-of-care diagnosis of pulmonary TB from urine samples$270,375
R21 · FY2016 · AI · contact PI